<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E4B5C8C4-E04B-4D88-9B70-44BFA5AF0534"><gtr:id>E4B5C8C4-E04B-4D88-9B70-44BFA5AF0534</gtr:id><gtr:name>Spanish National Research Council (CSIC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/97638AD0-D405-4372-ACA1-DEE19B7B4B12"><gtr:id>97638AD0-D405-4372-ACA1-DEE19B7B4B12</gtr:id><gtr:name>Ohio State University Wexner Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:department>School of Medicine</gtr:department><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E4B5C8C4-E04B-4D88-9B70-44BFA5AF0534"><gtr:id>E4B5C8C4-E04B-4D88-9B70-44BFA5AF0534</gtr:id><gtr:name>Spanish National Research Council (CSIC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/97638AD0-D405-4372-ACA1-DEE19B7B4B12"><gtr:id>97638AD0-D405-4372-ACA1-DEE19B7B4B12</gtr:id><gtr:name>Ohio State University Wexner Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E6201E8E-DEB5-49A6-BEA6-2E9940FACEBC"><gtr:id>E6201E8E-DEB5-49A6-BEA6-2E9940FACEBC</gtr:id><gtr:firstName>Claire</gtr:firstName><gtr:surname>Harris</gtr:surname><gtr:orcidId>0000-0003-0845-1730</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E8679824-FDB5-4146-9552-1FE7281A8ACF"><gtr:id>E8679824-FDB5-4146-9552-1FE7281A8ACF</gtr:id><gtr:firstName>Bryan</gtr:firstName><gtr:otherNames>Paul</gtr:otherNames><gtr:surname>Morgan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701298"><gtr:id>E02EC9FE-B883-4A17-B495-806F6201C33D</gtr:id><gtr:title>The role and diagnosis of complement dysregulation in disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701298</gtr:grantReference><gtr:abstractText>The proposed research addresses basic questions of how a central part of the immune system is controlled. It is relevant because understanding of these mechanisms and their disturbance in disease will better equip us to identify those at risk of disease to target prevention and treatment.
Complement is part of our immune defence against infection, a group of proteins in blood plasma that recognise, attack and destroy bacteria. This role of complement is important for health and people with complement defects are susceptible to infections. However, this defence comes at a price. Because of its powerful cell-killing properties, complement must be tightly controlled to prevent damage to our own cells resulting in disease. Recently, it has become apparent that small inherited changes in complement proteins, when present in specific combinations, affect this control and greatly increase the risk that complement will attack our own cells and damage organs, particularly kidney and eye. These include a common form of irreversible kidney failure in children (aHUS) and the commonest cause of blindness in the elderly (AMD). We plan to study the ways in which these small inherited changes (either common and called polymorphisms or rare and called mutations) in complement lead to loss of control. To do this we will first gain an understanding of how complement is normally activated and controlled using tools to study the ways that proteins interact. We will use these tools to test how the polymorphisms and mutations weaken control. This knowledge will be used to benefit health in two ways. First, we will develop simple and inexpensive blood tests to identify people carrying risky polymorphisms; those at risk can then be monitored closely to reduce the risk of getting disease. Second, better understanding of the problems in control will enable the design of appropriate treatments to restore control in the complement system to prevent and treat disease.
The work will be performed by a team with proven expertise in complement biology and genetics that has already made contributions to understanding how complement drives disease. The work involves analyses of proteins, either obtained from patients or healthy volunteers or manufactured in the laboratory, to discover how small changes in these proteins predispose to common diseases such as AMD and lethal disorders such as aHUS.</gtr:abstractText><gtr:technicalSummary>The proposed work will address the hypothesis that subtle effects on activation and regulation caused by common polymorphisms and rare mutations in components and regulators of the complement system synergise to cause dysregulation of complement that predisposes to disease. The hypothesis is built upon accumulating clinical evidence from patients with specific renal and ocular diseases but may have much broader relevance across many pathologies linked by chronic, low-grade inflammation and activation of the alternative pathway of complement. The research objectives are: first, to address how common polymorphisms (individual and in combination) in complement components and regulators affect the assembly, activity and regulation of the convertase enzymes; second, to determine how rare mutations in components and regulators identified in patients affect convertase assembly, activity and regulation; third, to develop tools for the rapid and efficient identification of disease-predisposing combinations of complement polymorphisms in plasma samples from individuals. The work will utilise state-of-the-art methods for analysing the effects of these polymorphisms and mutations on alternative pathway convertase function and regulation. These will include measures of intermolecular interactions using surface plasmon resonance, conformational changes using dual polarisation interferometry, and convertase function using assays of C3 cleavage, convertase decay and haemolytic capacity. These studies will utilise complement proteins and regulators either purified from plasma or recombinantly expressed as appropriate. The results will explain how individual mutations predispose to pathology and identify those combinations of complement polymorphisms that confer high risk of dysregulation and disease. To facilitate identification of individuals with high risk combinations of polymorphisms we will use proven methods to develop novel monoclonal antibodies that distinguish in plasma the relevant polymorphic variants. These will be used to develop simple immunoassays optimised for routine use to enable screening of relevant populations for disease risk. These assays will not only identify the complement polymorphic status of an individual but also quantify the various isoforms of components and regulators in plasma, information that further aids identification of those at risk of disease. The findings will be disseminated through publication and presentation at research and clinical meetings. Commercially exploitable findings will be patented prior to publication. Commercial partners will be involved at an early stage of assay development.</gtr:technicalSummary><gtr:fund><gtr:end>2011-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>631698</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Spanish National Research Council (CSIC)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>Madrid Collaboration</gtr:description><gtr:id>8EA0CE53-2CDE-4EE7-87D2-7C0CE24F077E</gtr:id><gtr:impact>Many publications in section 2 are collaborative with the Madrid lab. High impact -PNAS, JCI, HMG...

Three further manuscripts are in preparation.

Multi-disciplinary: cardiff group -protein biochemistry, functional assays; Madrid group -genetics, links to clinicians.</gtr:impact><gtr:outcomeId>1319D02EED6-1</gtr:outcomeId><gtr:partnerContribution>Collaborative research project, sharing experimental expertise, knowledge, data and reagents. Involves travel between the two labs for discussions (mini-conferences) and experimental work.</gtr:partnerContribution><gtr:piContribution>Experimental data, sharing of reagents and research tools, frequent meetings (at each institute) or by conference call.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Cellular Medicine</gtr:department><gtr:description>Newcastle collaboration</gtr:description><gtr:id>CC448E8B-DBC9-4274-9368-2A2AF33A8A52</gtr:id><gtr:impact>Manuscript published in Blood. Oral presentation at International complement Workshop, new york August 2010
Oral presentation at BSI meeting, liverpool, December 2010.

Multi-disciplinary. Newcastle group: clinicians and geneticists; Cardiff group: protein biochemists and experts in functional analyses.</gtr:impact><gtr:outcomeId>PYFmkMpxadh-1</gtr:outcomeId><gtr:partnerContribution>Sharing of reagents, expertise and data</gtr:partnerContribution><gtr:piContribution>First and joint senior author manuscript published in Blood. Newcastle identified disease-causing mutation in complement proteins using genetic techniques; Cardiff purified the mutant protein from plasma and functionally characterised the defect. Further manuscripts published.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Sir William Dunn School of Pathology</gtr:department><gtr:description>Oxford</gtr:description><gtr:id>3D5DA55E-F933-440E-BAB2-3E339A43ED69</gtr:id><gtr:impact>Shared reagents and expertise. Published PNAS.

Multi-disciplinary: structural biology (Oxford), functional analyses (Cardiff).</gtr:impact><gtr:outcomeId>kzqbRxMQDWw-1</gtr:outcomeId><gtr:partnerContribution>Shared reagents and research tools.
Experimental data. Published.</gtr:partnerContribution><gtr:piContribution>Purified plasma proteins using novel antibodies to send to oxford for structural analyses.
Oxford have sent recombinant reagents to cardiff for functional analyses.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>Imperial collaboration</gtr:description><gtr:id>8616A68B-2C7D-46F3-A1B7-83C1E53AF7C0</gtr:id><gtr:impact>Collaborator on a fellowship to further this work. Work was presented orally at International Complement meeting (Leiden) in 2011. Some of the work incorporated into 2013 paper with Lea, Oxford (PNAS).</gtr:impact><gtr:outcomeId>QGDymDuu6nQ-1</gtr:outcomeId><gtr:partnerContribution>Clinical analyses, protein purification, functional analyses.</gtr:partnerContribution><gtr:piContribution>Functional analysis of a mutant complement protein which causes aHUS. Advice on protein purification etc. Have hosted the RA from Imperial in the Cardiff lab to teach new techniques. Generated data for publication.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ohio State University Wexner Medical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Internal Medicine</gtr:department><gtr:description>USA autoantibody collaboration</gtr:description><gtr:id>443BEA32-8345-4567-A4FA-B03F26176E9B</gtr:id><gtr:impact>Collaboration instigated in August 2010; predict to publish in 2012/2013</gtr:impact><gtr:outcomeId>ES96AmWeG8t-1</gtr:outcomeId><gtr:partnerContribution>Provision of samples. Some analyses of complement proteins and antibodies.</gtr:partnerContribution><gtr:piContribution>Identification of autoantibodies against complement proteins in a cohort of SLE patients.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Chemistry</gtr:department><gtr:description>Edinburgh 1</gtr:description><gtr:id>E56AD12E-E1F9-463C-B54B-6CB729CD1952</gtr:id><gtr:impact>Manuscript published in JBC
Oral presentation at International Complement Workshop, new york, August 2010

Multi-disciplinary: Edinburgh group -protein expression and structural biology; Cardiff group -functional analyses.</gtr:impact><gtr:outcomeId>SLxBfvi3qbL-1</gtr:outcomeId><gtr:partnerContribution>Sharing of reagents and expertise.</gtr:partnerContribution><gtr:piContribution>Disease-causing mutations have been described in complement factor H by others. The Edingburgh group generated recombinant forms of these proteins and the Cardiff group characterised their functional deficit.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Human Genetics Unit</gtr:department><gtr:description>Edingburgh 2 collaboration</gtr:description><gtr:id>3EDB7575-F763-4D67-8B1D-E0EA368A1758</gtr:id><gtr:impact>Manuscript submitted.
Monoclonal antibodies have been generated and will be shared across groups.</gtr:impact><gtr:outcomeId>HKTMt9UMome-1</gtr:outcomeId><gtr:partnerContribution>A manuscript hs been prepared.</gtr:partnerContribution><gtr:piContribution>Functional analysis of a mutant protein thought to interfere with a complement protein.

We are currently making monoclonal antibodies against this protein.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Beacon Researchers in Schools</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F414E2CA-24F0-4E1A-ADBE-DD0368040412</gtr:id><gtr:impact>Postdoctoral scientist employed on grant talked to 6th form students about immunological research and described the project. In 2010 the students attended the laboratory to see how a research lab works.

Students were very enthusiastic and keen to visit the lab.</gtr:impact><gtr:outcomeId>A098A903363</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>49986</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>Kidneeds?</gtr:fundingOrg><gtr:id>3DC71612-0706-4AE2-94B1-949CC6C8B4C2</gtr:id><gtr:outcomeId>mnLvpkKDK87</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Complement standardistaion through ICS/ECN</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>542515A9-67E3-422D-A757-84DCCA9B6E80</gtr:id><gtr:outcomeId>jSZx5raU7ub</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Hybridomas secreting antibodies specific for complement proteins and polymorphic variants.</gtr:description><gtr:id>C0963F72-5507-40BB-B953-387EB71CCD0A</gtr:id><gtr:impact>Will contribute to future publications and collaborations. Our aim is to generate multiplexed assay panels for screening patient samples.</gtr:impact><gtr:outcomeId>E4CF999B9BB</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Monoclonal antibodies</gtr:title><gtr:type>Antibody</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Antibodies to disease-associated proteins to enable better analysis of their role in pathology.</gtr:description><gtr:id>CFF13FCA-07F1-494C-BE30-C73AF7E3E7EC</gtr:id><gtr:impact>Collaborative venture to generate antibodies to proeins involved in retinal diseases; anibodies (hybridomas) have been generated in Cardiff and will be sent to Edinburgh (collaboration 2).</gtr:impact><gtr:outcomeId>JVUwdsG2QZr</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Monoclonal antibodies</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>An in vitro assay using purified complement proteins that can illustrate the effect on overall complement activity of combining different polymorphic variants of complement activators and regulators.</gtr:description><gtr:id>926CE905-F2F7-4BF5-9C9C-AA46AA6AF1DC</gtr:id><gtr:impact>Five publications since 2009 use this methodology. Visitors have come to Cardiff from external collaborating labs to train in these techniques and take them back to their Institutes.</gtr:impact><gtr:outcomeId>F7F9DB8F0FC</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Complotype assay</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Antibodies have been developed on previous funding which can identify variants of factor H differing by just one amino acid. We have now developed this further by using these allele-specific antibodies to separate factor H variants in plasma of heterozygous individuals. This has proved valuable in patients with factor H-related pathologies as we can separate the variants and use the assays described in 7.1 (complotype assay) to dissect the mechanism underlying their disease.</gtr:description><gtr:id>2678A6BA-D1D9-4FDD-BB40-F3B0AB558D89</gtr:id><gtr:impact>Published in Blood, 2011 Francis NJ et al.
Oral presentation at national BSI meeting, 2010.
Oral presentation at international ECN meeting, Leiden 2011.</gtr:impact><gtr:outcomeId>103C88A7821</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Separation of Factor H allele products by affinity chromatography</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>185470D2-D87B-4DE5-A737-650C9E2A1BAD</gtr:id><gtr:title>The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/82659e599d16a5d950a336d66cb96edb"><gtr:id>82659e599d16a5d950a336d66cb96edb</gtr:id><gtr:otherNames>Mart?nez-Barricarte R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>5675e27fbc89f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F72FE76C-6E59-40EF-B045-588CE77B05D5</gtr:id><gtr:title>Variant-specific quantification of factor H in plasma identifies null alleles associated with atypical hemolytic uremic syndrome.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29c93f2d9d4c754ff4c4362079eb33d8"><gtr:id>29c93f2d9d4c754ff4c4362079eb33d8</gtr:id><gtr:otherNames>Hakobyan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>bnFG7vTbh9u</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD7A6B8B-862B-4272-9394-E9DA20A4BD0C</gtr:id><gtr:title>A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d68b1c72a0a8a59268e6560fe86a0eef"><gtr:id>d68b1c72a0a8a59268e6560fe86a0eef</gtr:id><gtr:otherNames>Paix?o-Cavalcante D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_540e157e157eecc9e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>593C9351-08BB-4273-910D-B23A5C60F2F4</gtr:id><gtr:title>Structural basis for complement factor I control and its disease-associated sequence polymorphisms.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b08a296c7000dcb2ab1061e6cb8b8bc"><gtr:id>3b08a296c7000dcb2ab1061e6cb8b8bc</gtr:id><gtr:otherNames>Roversi P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>Zu8g2W8NkDR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25259D1D-5EB3-4DE0-BE7A-65DA505F02FE</gtr:id><gtr:title>Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1480483434cc1935fe247857ad2fd60e"><gtr:id>1480483434cc1935fe247857ad2fd60e</gtr:id><gtr:otherNames>Heurich M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>0629471D_F0629471D_F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8598CBF9-03B1-409B-A806-6AB3A5659186</gtr:id><gtr:title>Lessons from functional and structural analyses of disease-associated genetic variants in the complement alternative pathway.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0464489b44f0523fcfb6ef275ec50298"><gtr:id>0464489b44f0523fcfb6ef275ec50298</gtr:id><gtr:otherNames>Rodr?guez de C?rdoba S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>nALjb44BywA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4CC15AE-2461-4A33-B6C5-B199193FBE88</gtr:id><gtr:title>A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be7f3be6b4153213b48fba9ec2faa3b7"><gtr:id>be7f3be6b4153213b48fba9ec2faa3b7</gtr:id><gtr:otherNames>Francis NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>j7k1Qgj6F74</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A92F545-41B1-4646-B034-2CE39641C8F9</gtr:id><gtr:title>The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7bd54a441c86eca9d7909b80c4885f7"><gtr:id>b7bd54a441c86eca9d7909b80c4885f7</gtr:id><gtr:otherNames>Tortajada A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>27AE43BF246</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F2A1B9C-90D6-45F6-BA27-F22D852C9A38</gtr:id><gtr:title>Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/82659e599d16a5d950a336d66cb96edb"><gtr:id>82659e599d16a5d950a336d66cb96edb</gtr:id><gtr:otherNames>Mart?nez-Barricarte R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>hsdsHeM5tkE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0F6283F-4A5A-4049-8B7E-025DADA609A4</gtr:id><gtr:title>Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/922ba5b31809ee1167263e42c9cf68fc"><gtr:id>922ba5b31809ee1167263e42c9cf68fc</gtr:id><gtr:otherNames>Montes T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>056118CEF28</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49372573-82EC-4D7C-B3FE-3E6E4E9D249A</gtr:id><gtr:title>Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d68b1c72a0a8a59268e6560fe86a0eef"><gtr:id>d68b1c72a0a8a59268e6560fe86a0eef</gtr:id><gtr:otherNames>Paix?o-Cavalcante D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>pm_15064_24_22854646</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37B7D78A-5A30-4404-9F9D-85232BAA8F40</gtr:id><gtr:title>C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7bd54a441c86eca9d7909b80c4885f7"><gtr:id>b7bd54a441c86eca9d7909b80c4885f7</gtr:id><gtr:otherNames>Tortajada A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>pm_15064_24_23728178</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3199AD2F-5F0B-4943-89FC-DB0618F55DB5</gtr:id><gtr:title>Postpartum aHUS secondary to a genetic abnormality in factor H acquired through liver transplantation.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3677fff7e8e7835c6a6b4e5b2c903158"><gtr:id>3677fff7e8e7835c6a6b4e5b2c903158</gtr:id><gtr:otherNames>Brown JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>pm_15064_24_22420623</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF0F9326-8F25-465B-A462-3BD955A8905C</gtr:id><gtr:title>Dense deposit disease.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7bdd0fe9638ad615fda1b25f1524a99"><gtr:id>f7bdd0fe9638ad615fda1b25f1524a99</gtr:id><gtr:otherNames>Smith RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>iouVecJwzw4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B136717-533A-4FCC-A260-1AF5D79352C9</gtr:id><gtr:title>The complotype: dictating risk for inflammation and infection.</gtr:title><gtr:parentPublicationTitle>Trends in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb211f11a91898556fae6da2b86b2165"><gtr:id>fb211f11a91898556fae6da2b86b2165</gtr:id><gtr:otherNames>Harris CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1471-4906</gtr:issn><gtr:outcomeId>pm_15064_24_22749446</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF7B2F8E-710D-46E6-BDC9-05F71C43D468</gtr:id><gtr:title>Complement dysregulation and disease: from genes and proteins to diagnostics and drugs.</gtr:title><gtr:parentPublicationTitle>Immunobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a75367826d58df4bd22aff237fb3bff0"><gtr:id>a75367826d58df4bd22aff237fb3bff0</gtr:id><gtr:otherNames>de Cordoba SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0171-2985</gtr:issn><gtr:outcomeId>pm_15064_24_22964229</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3647F303-86B6-49A6-96D3-B524ECCEB1F2</gtr:id><gtr:title>Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5b399fe95b803cf1dd7f9b31dd4f2ba"><gtr:id>f5b399fe95b803cf1dd7f9b31dd4f2ba</gtr:id><gtr:otherNames>Pechtl IC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>EA38C3A7_4EA38C3A7_4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7C01788-BAA4-4C7C-8BD0-7D0D4A23EE5B</gtr:id><gtr:title>Unique structure of iC3b resolved at a resolution of 24 &amp;Aring; by 3D-electron microscopy.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01162ce2bf11e723790e155a979fb00f"><gtr:id>01162ce2bf11e723790e155a979fb00f</gtr:id><gtr:otherNames>Alcorlo M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>h1SQLkGzsKi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>622DD8D0-2CDF-46E1-AC92-7BDC37080416</gtr:id><gtr:title>Dimerization of complement factor H-related proteins modulates complement activation in vivo.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/810476a30091e3fef131bda96842d834"><gtr:id>810476a30091e3fef131bda96842d834</gtr:id><gtr:otherNames>Goicoechea de Jorge E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_15064_24_23487775</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701298</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>